Literature DB >> 2761986

A new approach allowing an early prognosis in breast cancer: the ratio of estrogen receptor (ER) ligand binding activity to the ER-specific mRNA level.

E May1, H Mouriesse, F May-Levin, G Contesso, J C Delarue.   

Abstract

We have performed a quantitative analysis of steady-state levels of ER-mRNA for 88 untreated, primary breast carcinomas. We compared the amount of specific mRNA with the amount of ER receptor measured, through ligand binding activity, by calculating the ratio R = [ER-protein/ER-mRNA]. This analysis showed that the relative level of ER-mRNA displayed a large range of values partly related to the concentration of ER-protein. We found a greater percentage of tumors with a high R ratio value in the tumor population containing elevated levels of ER-protein. A statistical analysis performed on a homogeneous population of 63 patients shows no correlation between the R ratio, lymph-node involvement and histological grade. However, R appears to be significantly related to the risk of relapse within a relatively short period of time following the first observation. An R value higher than 1.5 appears to constitute a significant and early prognostic factor of recurrence (P = 0.003).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2761986

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology.

Authors:  C Carmeci; E C deConinck; T Lawton; D A Bloch; R J Weigel
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Reverse transcription-polymerase chain reaction (RT-PCR) assays of estrogen and progesterone receptors in breast cancer.

Authors:  S Chevillard; A Müller; C Levalois; C Lainé-Bidron; P Vielh; H Magdelénat
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Epidermal growth factor receptors and prognosis in primary breast cancer.

Authors:  F Spyratos; J C Delarue; C Andrieu; R Lidereau; M H Champème; K Hacène; M Brunet
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

4.  Truncated forms of DNA-binding estrogen receptors in human breast cancer.

Authors:  G K Scott; P Kushner; J L Vigne; C C Benz
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

Review 5.  c-erbB-2 oncogene as a prognostic marker in breast cancer.

Authors:  T J Perren
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

6.  Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression.

Authors:  E May; H Mouriesse; F May-Levin; J F Qian; P May; J C Delarue
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.